Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer

• Ngā kaituhi matua: Xiaomin Wan (Author), Xiaohui Zeng (Author), Liubao Peng (Author), Ye Peng (Author), Qiao Liu (Author), Lidan Yi (Author), Xia Luo (Author), Qijian Deng (Author), Chongqing Tan (Author)
• Hōputu: Pukapuka
• I whakaputaina: Frontiers Media S.A., 2021-08-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Objective: This study evaluated the cost-effectiveness of nivolumab plus ipilimumab vs. chemotherapy in the first-line setting for patients with advanced non-small-cell lung cancer (NSCLC) from the US payer perspective.Materials and methods: A Markov model wasdeveloped to evaluate the cost and effec...